Deimmunized flagellin and vaccine composition comprising same
The present invention relates to: deimmunized flagellin that does not induce the production of flagellin-specific antibodies; and use thereof. In particular, the present invention relates to a flagellin variant in which a major epitope that forms an antibody against flagellin is deleted, the flagellin variant being characterized by, when used as a vaccine adjuvant, not producing antibodies against flagellin while maintaining an excellent immune enhancer effect.
1 . A flagellin variant derived from Vibrio vulnificus comprising: N-terminal domain 2, N-terminal domain 3, and C-terminal domain 2,
wherein the amino acid sequence of SEQ ID NO: 1 is deleted from the flagellin variant.
2 . The flagellin variant of claim 1 , wherein the flagellin is flagellin B (FlaB).
3 . The flagellin variant of claim 1 , wherein the flagellin variant retains toll-like receptor 5 (TLR5) stimulatory activity.
4 . The flagellin variant of claim 1 , wherein the flagellin variant induces no flagellin-specific immune response.
5 . The flagellin variant of claim 1 , wherein the flagellin variant has an immune boosting effect.
6 . A vaccine composition comprising the flagellin variant of claim 1 and at least one antigen.
7 . A flu vaccine composition comprising the flagellin variant of claim 1 as an adjuvant.